Today Stories

World antibiotic awareness week 18 to 25 November 2022 In 2019, it was estimated that 1.2 million deaths globally, were due to antibiotic-resistant infections1. In England, during 2019/20, there were over 90,000 hospital admissions2 – yet the global pipeline for new antibiotics to address this growing problem has been failing. This year’s World Antimicrobial Awareness Week aims to improve the awareness and understanding of antimicrobial resistance (AMR). The event seeks to encourage best practices among the public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance. We are now living in an age where drug resistant microbes are developing faster than new antimicrobial treatments, which poses a huge threat to modern medicine. Amit Aggarwal, Ex…

London, U.K., 17 November 2022: Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces its expansion into the U.K. with the acquisition of multi-site company Egin Research. Velocity is the first US-based clinical research sites business to expand into Europe, bringing its total number of dedicated research locations to 42. The addition of Egin Research’s two sites increases Velocity’s European site footprint to three, after its first European purchase in Hamburg, Germany in July 2022 and further growth expected over the next 12 months. Dominic Clavell, Executive Vice President, Europe, said, “The size and importance of the UK market for clinical research cannot be underestimated. There is a focus on clinical trial regulation reform in a…

Company also announces £100 million investment over next ten years to support health system strengthening and access initiatives in lower income countries GSK ranks 1st in the 2022 Access to Medicine Index (ATMI) report published today. The Index is an independent, investor-backed report that ranks 20 of the world’s largest pharmaceutical companies on progress to improve access in 108 lower income countries and focuses on 83 high burden priority diseases. Emma Walmsley, Chief Executive Officer, GSK, said: “We are delighted to have ranked first in the Access to Medicine Index (ATMI) for the eighth consecutive time. This is recognition of the action we are taking to get ahead of disease together and improve access to medicine and vaccines in lower income countries, and I want to thank all of…

Establishes first-in-class biopharmaceutical commercialization platform specifically addressing rare diseases in Europe Secured exclusive rights in 26 European Countries to an investigational orphan medicine for the treatment of an ultra-rare ophthalmologic disease, currently under review by the European Medicines Agency for marketing approval Founded by biopharmaceutical executives Adam Plich, CEO, and Anant Murthy, Board Advisor, with the backing of a seasoned Advisory Board AMSTERDAM--(BUSINESS WIRE)--Today, Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”) officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical orig…

Los Angeles, California, USA, November 15, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, today announced the signing of a new multi-year, non-exclusive license agreement with DynamiCure Biotechnology, a private biopharmaceutical company developing innovative therapeutic antibody candidates to treat cancer, autoimmune disorders, and other diseases.  Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPETTM to DynamiCure Biotechnology for use in its clinical trial. Commenting on the announcement, Ian Wilson, CEO of ImaginAb, said: “We are delighted that DynamiCure Biotechnology will be using our CD8 ImmunoPET…

Positive opinion based on TOPAZ-1 Phase III trial updated survival results showing Imfinzi combination reduced risk of death by 24% vs. chemotherapy alone AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on the primary results from the TOPAZ-1 Phase III trial published in the New England Journal of Medicine Evidence, and on the updated results presented at the European Society for Medical Oncology Congress 2022. At the interim analysis, Imfinz…

Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix will continue its start-up approach as a standalone entity wholly-owned by Bayer  Monheim, November 10, 2022 – Bayer announced today the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) uses novel systems biology and computational life science tools to identify new modes of action for crop protection compounds. The Targenomix expertise, personnel, and platforms will be an important part of delivering on Bayer’s commitment to the design of sa…

Brandon Capital announces its participation in NRG Therapeutics’ £16 million (AUD$29m) Series A alongside Omega Funds NRG is developing inhibitors of a first-in-class target as a potential disease-modifying treatment for Parkinson's and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) towards the clinic The financing enables UK-headquartered NRG Therapeutics to expand its research team in Australia led by Prof Seth Masters under an agreement with WEHI (Walter and Eliza Hall Institute of Medical Research) Jonathan Tobin, Partner at Brandon Capital, joins the NRG board; and Prof Masters joins the management team as VP Discovery Biology Melbourne, Australia and London UK, 9 November 2022 – Brandon Capital, Australasia’s leading life science venture capital firm…

Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared through platform interface may help healthcare providers make data-driven decisions± about care for adults treated with select Lilly insulins Offers compatibility with the Dexcom® Continuous Glucose Monitoring Systems, *,∞ the Tempo Blood Glucose Monitor (BGM) and other compatible BGMs, as well as wearable devices from Fitbit®, Garmin®, Google Fit® and the Apple Health app INDIANAPOLIS, Nov. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 dia…

Singleron Biotechnologies, a leader in single cell multi-omics analysis, is happy to announce the opening of their brand-new laboratories in Cologne, Germany, dedicated to showcasing their vast single cell sequencing solutions, from instruments to novel kits tailored for many different research applications. Through customer demonstrations, these modern laboratories will provide potential customers a hands-on approach allowing the opportunity to test the latest developments Singleron has to offer in single cell sequencing. The laboratories will also augment Singleron’s productivity to extend operations in research and development of novel products to further Singleron’s innovative technology portfolio. The new state of the art laboratory will complement the already established single cell…

Educators and school officials encouraged to drive student awareness of state and regional science fairs for a chance to enter nation’s premier middle school STEM competition WALTHAM, Mass. & WASHINGTON--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Society for Science (the Society), today announced the Thermo Fisher Scientific Junior Innovators Challenge, the nation’s premier middle school science, technology, engineering and math (STEM) competition. The Society named Thermo Fisher as the new title sponsor of the organization’s middle school STEM competition in August. “Society for Science is very excited to embark on this new partnership with Thermo Fisher Scientific,” said Maya Ajmera, President and CEO of Society for Science a…

LEIDEN, The Netherlands, November 02, 2022 / B3C newswire / -- MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position. Henk Volberda, chairman of the jury and professor of Strategy & Innovation at the University of Amsterdam: “MIMETAS is world-leading. Since its foundation in 2013, the company has grown considerably, with branches in Europe, the USA, and Asia. It can now count the largest pharmaceutical companies worldwide among its partners. With its miniaturized organs-on-a-chip, MIMETAS has found a promising approach to enable major advancements in the pharmaceutical industry.” “The…

Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart RecoveryTransaction to Bring Lifesaving Innovations to More Patients with Unmet NeedExpected to Enhance Johnson & Johnson’s Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction New Brunswick, N.J. and Danvers, Mass., November 1, 2022 – Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender o…

– Leaders in biotech and genomics to launch more personalised genomic solutions to more than 10,000 people across the Baltics and Mediterranean regions – L’AQUILA, Italy, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Biotechnology startup Longenesis has partnered with Dante Genomics, a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants. WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and availability of practitioners, servic…

Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billion, or $2.6 billion at current exchange rates. Serving clinicians and laboratory pro…

– Genomic Biopharma Inc. to present abstracts on two drug candidate programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting – NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, today announced the creation of Genomic Biopharma Inc., a separate drug discovery and development company to distinguish the separate business streams of each entity. Genomic Biopharma Inc. will present two abstracts on two drug programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting, the first of which is a top scoring abstract at the meeting titled: Abstract Title: A computational approach to design a COVID-19 vaccine against a predicted SARS-CoV-2 variant: high immunogenicity, efficacy and safety of DELLERA v…

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN’S SYNDROME (“SJS”) AND SYSTEMIC LUPUS ERYTHEMATOSUS (“SLE”) HANNOVER MEDICAL SCHOOL (“MHH”) WILL COLLECT BIOSAMPLES FROM SJS AND SLE PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE DRUG DISCOVERY Hamburg, Germany, 25 October 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to generate a molecular patient database for Sjögren’s syndrome (“SjS”) and systemic lupus erythematosus (“SLE”).The strategic partnership between Evotec…

Also known as a form of blood cancer, Myelodysplastic syndromes (MDS) are an often unrecognised, under-diagnosed rare group of bone marrow failure disorders, where the body no longer makes enough healthy, normal blood cells in the bone marrow. There are many different types of MDS, with some types staying mild for years and others becoming more serious. Although MDS can affect people of any age, it is most common in adults over the age of 60. MDS World Awareness Day Every year on October 25th, the MDS Alliance and member groups across the world come together to raise awareness of MDS. This year, the Alliance is sharing information on the signs and symptoms of MDS and highlighting the importance of getting a blood test with a full blood count analysis to confirm a diagnosis. The four main…

Leicester-based procurement services organisation Unimed Procurement Services (Unimed) has joined forces with International Health Partners (IHP) to create a long-lasting partnership dedicated to supplying life-saving medical supplies to countries in need. In line with the two organisations’ mutual objective to increase accessibility to essential medical products and supplies to countries that are unable to access basic resources, the ongoing partnership involves several shipments of a variety of products donated by Unimed, a contribution worth $69,000. As the largest coordinator of donated medical products in the UK and Europe, IHP works with a strong network of global healthcare industry donors, and will coordinate the placement and safe transport of the products to their in-country NGO…

-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases -- The company's proprietary HEPTAD platform will extend AbbVie's current discovery research capabilities by generating potential novel antibodies against difficult-to-drug protein targets in immunology and beyond NORTH CHICAGO, Ill., Oct. 20, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS's lead program is DJS-002,…